Starpharma Reports Revenue Growth and Regulatory Milestone for DEP® SN38

Starpharma Holdings Limited ( (AU:SPL) ) has provided an update.

Starpharma Holdings Limited reported a 65% increase in adjusted revenue for the half-year ending December 2024, driven by research revenue from Petalion Therapeutics and increased product sales. The company also achieved a 29% reduction in operating loss, attributed to the completion of several DEP® clinical programs. A significant regulatory milestone was reached with the FDA’s positive feedback on the DEP® SN38 clinical pathway, enhancing its potential for treating platinum-resistant ovarian cancer. This progress, alongside ongoing partnerships and asset optimization, positions Starpharma for future growth and stakeholder engagement.

More about Starpharma Holdings Limited

Starpharma Holdings Limited is an innovative biotechnology company based in Melbourne, Australia, specializing in dendrimer technology. The company focuses on developing DEP® drug delivery systems and products like Viraleze™ and VivaGel® BV, with a market focus on pharmaceuticals and healthcare solutions.

YTD Price Performance: 5.71%

Average Trading Volume: 18,507

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $30.5M

For a thorough assessment of SPL stock, go to TipRanks’ Stock Analysis page.